{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:02:24Z","timestamp":1790946144522,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06270"],"award-info":[{"award-number":["23K06270"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02838-7","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:08:35Z","timestamp":1750144115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Overexpression of miR-29a and miR-29b is involved in imatinib resistance via abrogated NF1 expression and increased ERK1\/2 activation in chronic myeloid leukemia cells"],"prefix":"10.1007","volume":"42","author":[{"given":"Masanobu","family":"Tsubaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Obana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuichi","family":"Koumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"6","key":"2838_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792.","journal-title":"Am J Hematol"},{"issue":"9","key":"2838_CR2","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1038\/bcj.2016.79","volume":"6","author":"S Harrach","year":"2016","unstructured":"Harrach S, Schmidt-Lauber C, Pap T, Pavenst\u00e4dt H, Schlatter E, Schmidt E, Berdel WE, Schulze U, Edemir B, Jeromin S, Haferlach T, Ciarimboli G, Bertrand J. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer J. 2016;6(9):e470. https:\/\/doi.org\/10.1038\/bcj.2016.79.","journal-title":"Blood Cancer J"},{"issue":"6","key":"2838_CR3","doi-asserted-by":"publisher","first-page":"e13420","DOI":"10.1111\/cpr.13420","volume":"56","author":"M Tsubaki","year":"2023","unstructured":"Tsubaki M, Takeda T, Koumoto Y, Usami T, Matsuda T, Seki S, Sakai K, Nishio K, Nishida S. Activation of ERK1\/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells. Cell Prolif. 2023;56(6):e13420. https:\/\/doi.org\/10.1111\/cpr.13420.","journal-title":"Cell Prolif"},{"issue":"1","key":"2838_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/leu.2016.179","volume":"31","author":"LN Eadie","year":"2017","unstructured":"Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. 2017;31(1):75\u201382. https:\/\/doi.org\/10.1038\/leu.2016.179.","journal-title":"Leukemia"},{"issue":"1","key":"2838_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17(1):49. https:\/\/doi.org\/10.1186\/s12943-018-0780-6.","journal-title":"Mol Cancer"},{"issue":"6","key":"2838_CR6","doi-asserted-by":"publisher","first-page":"8465","DOI":"10.1002\/jcp.27776","volume":"234","author":"R Mardani","year":"2019","unstructured":"Mardani R, Jafari Najaf Abadi MH, Motieian M, Taghizadeh-Boroujeni S, Bayat A, Farsinezhad A, Gheibi Hayat SM, Motieian M, Pourghadamyari H. MicroRNA in leukemia: tumor suppressors and oncogenes with prognostic potential. J Cell Physiol. 2019;234(6):8465\u201386. https:\/\/doi.org\/10.1002\/jcp.27776.","journal-title":"J Cell Physiol"},{"issue":"6","key":"2838_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.4149\/neo_2015_115","volume":"62","author":"D Jurkovicova","year":"2015","unstructured":"Jurkovicova D, Lukackova R, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Chovanec M. microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. Neoplasma. 2015;62(6):949\u201358. https:\/\/doi.org\/10.4149\/neo_2015_115.","journal-title":"Neoplasma"},{"issue":"4","key":"2838_CR8","doi-asserted-by":"publisher","first-page":"e61858","DOI":"10.1371\/journal.pone.0061858","volume":"8","author":"Y Li","year":"2013","unstructured":"Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang Z, Zhong L, Cao W, Wen J, Feng W. Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS ONE. 2013;8(4):e61858. https:\/\/doi.org\/10.1371\/journal.pone.0061858.","journal-title":"PLoS ONE"},{"issue":"24","key":"2838_CR9","doi-asserted-by":"publisher","first-page":"38717","DOI":"10.18632\/oncotarget.16314","volume":"8","author":"M Tsubaki","year":"2017","unstructured":"Tsubaki M, Takeda T, Kino T, Sakai K, Itoh T, Imano M, Nakayama T, Nishio K, Satou T, Nishida S. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells. Oncotarget. 2017;8(24):38717\u201330. https:\/\/doi.org\/10.18632\/oncotarget.16314.","journal-title":"Oncotarget"},{"issue":"1","key":"2838_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41374-018-0114-8","volume":"99","author":"M Tsubaki","year":"2019","unstructured":"Tsubaki M, Takeda T, Tomonari Y, Koumoto YI, Imano M, Satou T, Nishida S. Overexpression of HIF-1\u03b1 contributes to melphalan resistance in multiple myeloma cells by activation of ERK1\/2, Akt, and NF-\u03baB. Lab Invest. 2019;99(1):72\u201384. https:\/\/doi.org\/10.1038\/s41374-018-0114-8.","journal-title":"Lab Invest"},{"issue":"10","key":"2838_CR11","doi-asserted-by":"publisher","first-page":"16784","DOI":"10.18632\/oncotarget.15159","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu Q, Yan H, Tao SQ, Wang XN, Mou L, Chen P, Cheng XW, Wu WY, Wu ZS. XIAP 3\u2019-untranslated region as a ceRNA promotes FSCN1 function in inducing the progression of breast cancer by binding endogenous miR-29a-5p. Oncotarget. 2017;8(10):16784\u2013800. https:\/\/doi.org\/10.18632\/oncotarget.15159.","journal-title":"Oncotarget"},{"issue":"2","key":"2838_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jcp.29062","volume":"235","author":"A De Blasio","year":"2020","unstructured":"De Blasio A, Di Fiore R, Pratelli G, Drago-Ferrante R, Saliba C, Baldacchino S, Grech G, Scerri C, Vento R, Tesoriere G. A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 triple-negative breast cancer cells. J Cell Physiol. 2020;235(2):629\u201337. https:\/\/doi.org\/10.1002\/jcp.29062.","journal-title":"J Cell Physiol"},{"issue":"4","key":"2838_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/ibd\/izz281","volume":"26","author":"A Wang","year":"2020","unstructured":"Wang A, Deng S, Chen X, Yu C, Du Q, Wu Y, Chen G, Hu L, Hu C, Li Y. miR-29a-5p\/STAT3 positive feedback loop regulates TETs in colitis-associated colorectal cancer. Inflamm Bowel Dis. 2020;26(4):524\u201333. https:\/\/doi.org\/10.1093\/ibd\/izz281.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"2838_CR14","doi-asserted-by":"publisher","first-page":"e52393","DOI":"10.1371\/journal.pone.0052393","volume":"7","author":"HT Zhu","year":"2012","unstructured":"Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS ONE. 2012;7(12):e52393. https:\/\/doi.org\/10.1371\/journal.pone.0052393.","journal-title":"PLoS ONE"},{"issue":"2","key":"2838_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/jcm8020273","volume":"8","author":"M Kurihara-Shimomura","year":"2019","unstructured":"Kurihara-Shimomura M, Sasahira T, Shimomura H, Nakashima C, Kirita T. The oncogenic activity of miR-29b-1-5p induces the epithelial-mesenchymal transition in oral squamous cell carcinoma. J Clin Med. 2019;8(2):273. https:\/\/doi.org\/10.3390\/jcm8020273.","journal-title":"J Clin Med"},{"issue":"30","key":"2838_CR16","doi-asserted-by":"publisher","first-page":"49451","DOI":"10.18632\/oncotarget.17706","volume":"8","author":"S Salati","year":"2017","unstructured":"Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A, Castagnetti F, Gugliotta G, Rosti G, Bergamaschi M, Tafuri A, Tagliafico E, Lemoli R, Manfredini R. Deregulated expression of miR-29a-3p, miR-494\u20133p and miR-660\u20135p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget. 2017;8(30):49451\u201369. https:\/\/doi.org\/10.18632\/oncotarget.17706.","journal-title":"Oncotarget"},{"issue":"1","key":"2838_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17\u201333. https:\/\/doi.org\/10.1016\/j.cell.2017.06.009.","journal-title":"Cell"},{"issue":"25","key":"2838_CR18","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, J\u00e4nne PA, Aguirre AJ. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021;384(25):2382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2105281.","journal-title":"N Engl J Med"},{"issue":"1","key":"2838_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-022-01583-z","volume":"21","author":"M Berlak","year":"2022","unstructured":"Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, da Costa BM, Barker K, Fyle E, Calton E, Eising S, Ober K, Hughes D, Koutroumanidou E, Carter P, Stankunaite R, Proszek P, Jain N, Rosswog C, Dorado-Garcia H, Molenaar JJ, Hubank M, Barone G, Anderson J, Lang P, Deubzer HE, K\u00fcnkele A, Fischer M, Eggert A, Kloft C, Henssen AG, Boettcher M, Hertwig F, Bl\u00fcthgen N, Chesler L, Schulte JH. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Mol Cancer. 2022;21(1):126. https:\/\/doi.org\/10.1186\/s12943-022-01583-z.","journal-title":"Mol Cancer"},{"issue":"1","key":"2838_CR20","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1038\/s41467-021-27093-y","volume":"12","author":"AE Smith","year":"2021","unstructured":"Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021;12(1):6667. https:\/\/doi.org\/10.1038\/s41467-021-27093-y.","journal-title":"Nat Commun"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02838-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02838-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02838-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:39:32Z","timestamp":1751531972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02838-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2838"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02838-7","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"268"}}